Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 3476240, 8 pages
http://dx.doi.org/10.1155/2016/3476240
Review Article

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials

1Department of Neurosciences Clinical Imaging, Chair of Psychiatry, “G. d’Annunzio” University, 65100 Chieti, Italy
2Polyedra Research Group, 64100 Teramo, Italy
3NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4, 64100 Teramo, Italy
4Villa S. Giuseppe Hospital, Hermanas Hospitalarias, 63100 Ascoli Piceno, Italy
5School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK
6New York State Psychiatric Institute, Columbia University, New York, NY 10027, USA

Received 31 January 2016; Revised 23 June 2016; Accepted 27 June 2016

Academic Editor: Vera L. Petricevich

Copyright © 2016 Stefano Marini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. van Os and S. Kapur, “Schizophrenia,” The Lancet, vol. 374, no. 9690, pp. 635–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. J. H. Ebisch, A. Salone, F. Ferri et al., “Out of touch with reality? Social perception in first-episode schizophrenia,” Social Cognitive and Affective Neuroscience, vol. 8, no. 4, pp. 394–403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Y. Meltzer and S. M. Stahl, “The dopamine hypothesis of schizophrenia: a review,” Schizophrenia Bulletin, vol. 2, no. 1, pp. 19–76, 1976. View at Publisher · View at Google Scholar · View at Scopus
  4. D. R. Weinberger, “Implications of normal brain development for the pathogenesis of schizophrenia,” Archives of General Psychiatry, vol. 44, no. 7, pp. 660–669, 1987. View at Publisher · View at Google Scholar · View at Scopus
  5. K. L. Davis, R. S. Kahn, G. Ko, and M. Davidson, “Dopamine in schizophrenia: a review and reconceptualization,” American Journal of Psychiatry, vol. 148, no. 11, pp. 1474–1486, 1991. View at Publisher · View at Google Scholar · View at Scopus
  6. E. D. Luby, J. S. Gottlieb, B. D. Cohen, G. Rosenbaum, and E. F. Domino, “Model psychoses and schizophrenia,” American Journal of Psychiatry, vol. 119, no. 1, pp. 61–67, 1962. View at Publisher · View at Google Scholar
  7. D. C. Javitt and S. R. Zukin, “Recent advances in the phencyclidine model of schizophrenia,” The American Journal of Psychiatry, vol. 148, no. 10, pp. 1301–1308, 1991. View at Publisher · View at Google Scholar · View at Scopus
  8. J. H. Krystal, L. P. Karper, J. P. Seibyl et al., “Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses,” Archives of General Psychiatry, vol. 51, no. 3, pp. 199–214, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. C. M. Adler, A. K. Malhotra, I. Elman et al., “Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia,” The American Journal of Psychiatry, vol. 156, no. 10, pp. 1646–1649, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. A. C. Lahti, M. A. Weiler, T. Michaelidis, A. Parwani, and C. A. Tamminga, “Effects of ketamine in normal and schizophrenic volunteers,” Neuropsychopharmacology, vol. 25, no. 4, pp. 455–467, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. A. K. Malhotra, D. A. Pinals, C. M. Adler et al., “Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics,” Neuropsychopharmacology, vol. 17, no. 3, pp. 141–150, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. J. T. Kantrowitz and D. C. Javitt, “N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?” Brain Research Bulletin, vol. 83, no. 3-4, pp. 108–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. M. Behrens, S. S. Ali, and L. L. Dugan, “Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia,” The Journal of Neuroscience, vol. 28, no. 51, pp. 13957–13966, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Tancredi, M. D'Antuono, C. Cafè et al., “The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK,” Journal of Neurochemistry, vol. 75, no. 2, pp. 634–643, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Balschun, W. Wetzel, A. Del Rey et al., “Interleukin-6: a cytokine to forget,” The FASEB Journal, vol. 18, no. 14, pp. 1788–1790, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Braida, P. Sacerdote, A. E. Panerai et al., “Cognitive function in young and adult IL (interleukin)-6 deficient mice,” Behavioural Brain Research, vol. 153, no. 2, pp. 423–429, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. C. J. Heyser, E. Masliah, A. Samimi, I. L. Campbell, and L. H. Gold, “Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 4, pp. 1500–1505, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. F. M. Benes and S. Berretta, “GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder,” Neuropsychopharmacology, vol. 25, no. 1, pp. 1–27, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. D. A. Lewis and B. Moghaddam, “Cognitive dysfunction in schizophrenia: convergence of γ-aminobutyric acid and glutamate alterations,” Archives of Neurology, vol. 63, no. 10, pp. 1372–1376, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. L. F. Martin and R. Freedman, “Schizophrenia and the α7 nicotinic acetylcholine receptor,” International Review of Neurobiology, vol. 78, pp. 225–246, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. S. Brown, M. D. Begg, S. Gravenstein et al., “Serologic evidence of prenatal influenza in the etiology of schizophrenia,” Archives of General Psychiatry, vol. 61, no. 8, pp. 774–780, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. P. B. Mortensen, B. Nørgaard-Pedersen, B. L. Waltoft et al., “Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth,” Biological Psychiatry, vol. 61, no. 5, pp. 688–693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. S. Brown, C. A. Schaefer, C. P. Quesenberry Jr., L. Liu, V. P. Babulas, and E. S. Susser, “Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring,” The American Journal of Psychiatry, vol. 162, no. 4, pp. 767–773, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Babulas, P. Factor-Litvak, R. Goetz, C. A. Schaefer, and A. S. Brown, “Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia,” The American Journal of Psychiatry, vol. 163, no. 5, pp. 927–929, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. S. L. Buka, M. T. Tsuang, E. F. Torrey, M. A. Klebanoff, D. Bernstein, and R. H. Yolken, “Maternal infections and subsequent psychosis among offspring,” Archives of General Psychiatry, vol. 58, no. 11, pp. 1032–1037, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. S. L. Buka, T. D. Cannon, E. F. Torrey, and R. H. Yolken, “Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring,” Biological Psychiatry, vol. 63, no. 8, pp. 809–815, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-Y. Chen, Y.-L. Huang, and T.-H. Lin, “Association between oxidative stress and cytokine production in nickel- treated rats,” Archives of Biochemistry and Biophysics, vol. 356, no. 2, pp. 127–132, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Yan, R. K. Ohls, C. Rosa, M. Shah, D. S. Richards, and R. D. Christensen, “Maternal and umbilical serum concentrations of granulocyte colony-stimulating factor and its messenger RNA during clinical chorioamnionitis,” Obstetrics and Gynecology, vol. 86, no. 3, pp. 428–432, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. W. A. Banks, A. J. Kastin, and E. G. Gutierrez, “Penetration of interleukin-6 across the murine blood-brain barrier,” Neuroscience Letters, vol. 179, no. 1-2, pp. 53–56, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. B. J. Miller, P. Buckley, W. Seabolt, A. Mellor, and B. Kirkpatrick, “Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects,” Biological Psychiatry, vol. 70, no. 7, pp. 663–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Fan, D. C. Goff, and D. C. Henderson, “Inflammation and schizophrenia,” Expert Review of Neurotherapeutics, vol. 7, no. 7, pp. 789–796, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Potvin, E. Stip, A. A. Sepehry, A. Gendron, R. Bah, and E. Kouassi, “Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review,” Biological Psychiatry, vol. 63, no. 8, pp. 801–808, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. R. C. Drexhage, E. M. Knijff, R. C. Padmos et al., “The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder,” Expert Review of Neurotherapeutics, vol. 10, no. 1, pp. 59–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. H.-J. Möller, “Clinical evaluation of negative symptoms in schizophrenia,” European Psychiatry, vol. 22, no. 6, pp. 380–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Tandon, H. A. Nasrallah, and M. S. Keshavan, “Schizophrenia, ‘just the facts’ 4. Clinical features and conceptualization,” Schizophrenia Research, vol. 110, no. 1–3, pp. 1–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. J. M. Holden, J. E. Meyers-Manor, J. B. Overmier, E. Gahtan, W. Sweeney, and H. Miller, “Lipopolysaccharide-induced immune activation impairs attention but has little effect on short-term working memory,” Behavioural Brain Research, vol. 194, no. 2, pp. 138–145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Brydon, N. A. Harrison, C. Walker, A. Steptoe, and H. D. Critchley, “Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans,” Biological Psychiatry, vol. 63, no. 11, pp. 1022–1029, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Dickerson, C. Stallings, A. Origoni, J. Boronow, and R. Yolken, “C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia,” Schizophrenia Research, vol. 93, no. 1–3, pp. 261–265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Pedersen, M. Diedrich, F. Kaestner et al., “Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 8, pp. 1789–1792, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Liu, F. Jia, G. Yuan et al., “Tyrosine hydroxylase, interleukin-1β and tumor necrosis factor-α are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis,” Psychiatry Research, vol. 176, no. 1, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Zalcman, J. M. Green-Johnson, L. Murray et al., “Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6,” Brain Research, vol. 643, no. 1-2, pp. 40–49, 1994. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Hayley, P. Wall, and H. Anisman, “Sensitization to the neuroendocrine, central monoamine and behavioural effects of murine tumor necrosis factor-α: peripheral and central mechanisms,” European Journal of Neuroscience, vol. 15, no. 6, pp. 1061–1076, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. A. J. Dunn, “Effects of cytokines and infections on brain neurochemistry,” Clinical Neuroscience Research, vol. 6, no. 1-2, pp. 52–68, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. Y.-K. Kim, L. Kim, and M.-S. Lee, “Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics,” Schizophrenia Research, vol. 44, no. 3, pp. 165–175, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. X. Y. Zhang, D. F. Zhou, L. Y. Cao, G. Y. Wu, and Y. C. Shen, “Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics,” Neuropsychopharmacology, vol. 30, no. 8, pp. 1532–1538, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Y. Zhang, D. F. Zhou, L. Y. Qi et al., “Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics,” Psychopharmacology, vol. 204, no. 1, pp. 177–184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Ozek, K. Toreci, I. Akkok, and Z. Guvener, “Influence of therapy on antibody-formation,” Psychopharmacologia, vol. 21, pp. 401–412, 1971. View at Google Scholar
  48. M. J. Schwarz, M. Riedel, M. Ackenheil, and N. Müller, “Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients,” Biological Psychiatry, vol. 47, no. 1, pp. 29–33, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Wilke, V. Arolt, M. Rothermundt, C. Weitzsch, M. Hornberg, and H. Kirchner, “Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients,” European Archives of Psychiatry and Clinical Neuroscience, vol. 246, no. 5, pp. 279–284, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Maes, E. Bosmans, R. Ranjan et al., “Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs,” Schizophrenia Research, vol. 21, no. 1, pp. 39–50, 1996. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Maes, E. Bosmans, G. Kenis, R. De Jong, R. S. Smith, and H. Y. Meltzer, “In vivo immunomodulatory effects of clozapine in schizophrenia,” Schizophrenia Research, vol. 26, no. 2-3, pp. 221–225, 1997. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Müller, M. Empl, M. Riedel, M. Schwarz, and M. Ackenheil, “Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia,” European Archives of Psychiatry and Clinical Neuroscience, vol. 247, no. 6, pp. 308–313, 1997. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Song, A.-H. Lin, G. Kenis, E. Bosmans, and M. Maes, “Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist,” Schizophrenia Research, vol. 42, no. 2, pp. 157–164, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. C. L. Cazzullo, E. Sacchetti, A. Galluzzo et al., “Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 26, no. 1, pp. 33–39, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Sirota, M. Meiman, R. Herschko, and H. Bessler, “Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients,” Psychiatry Research, vol. 134, no. 2, pp. 151–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. X.-Q. Song, L.-X. Lv, W.-Q. Li, Y.-H. Hao, and J.-P. Zhao, “The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia,” Biological Psychiatry, vol. 65, no. 6, pp. 481–488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Sugino, T. Futamura, Y. Mitsumoto, K. Maeda, and Y. Marunaka, “Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, no. 2, pp. 303–307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. Y.-K. Kim, A.-M. Myint, R. Verkerk, S. Scharpe, H. Steinbusch, and B. Leonard, “Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients,” Neuropsychobiology, vol. 59, no. 2, pp. 123–129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Müller, P. Dobmeier, M. Empl, M. Riedel, M. Schwarz, and M. Ackenheil, “Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients,” European Psychiatry, vol. 12, no. 6, pp. 294–299, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Pollmächer, M. Haack, A. Schuld, T. Kraus, and D. Hinze-Selch, “Effects of antipsychotic drugs on cytokine networks,” Journal of Psychiatric Research, vol. 34, no. 6, pp. 369–382, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. Ł. Drzyzga, E. Obuchowicz, A. Marcinowska, and Z. S. Herman, “Cytokines in schizophrenia and the effects of antipsychotic drugs,” Brain, Behavior, and Immunity, vol. 20, no. 6, pp. 532–545, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Lin, G. Kenis, S. Bignotti et al., “The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6,” Schizophrenia Research, vol. 32, no. 1, pp. 9–15, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. N. Gogtay, A. Lu, A. D. Leow et al., “Three-dimensional brain growth abnormalities in childhood-onset schizophrenia visualized by using tensor-based morphometry,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 41, pp. 15979–15984, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. R. G. Steen, C. Mull, R. McClure, R. M. Hamer, and J. A. Lieberman, “Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies,” The British Journal of Psychiatry, vol. 188, pp. 510–518, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. E. M. Meisenzahl, D. Rujescu, A. Kirner et al., “Association of an interleukin-1β genetic polymorphism with altered brain structure in patients with schizophrenia,” The American Journal of Psychiatry, vol. 158, no. 8, pp. 1316–1319, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. D. L. Garver, R. L. Tamas, and J. A. Holcomb, “Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype,” Neuropsychopharmacology, vol. 28, no. 8, pp. 1515–1520, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Doorduin, E. F. J. de Vries, A. T. M. Willemsen, J. C. De Groot, R. A. Dierckx, and H. C. Klein, “Neuroinflammation in schizophrenia-related psychosis: a PET study,” Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1801–1807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. B. N. van Berckel, M. G. Bossong, R. Boellaard et al., “Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study,” Biological Psychiatry, vol. 64, no. 9, pp. 820–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Takano, R. Arakawa, H. Ito et al., “Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106,” International Journal of Neuropsychopharmacology, vol. 13, no. 7, pp. 943–950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. T. A. Bayer, R. Buslei, L. Havas, and P. Falkai, “Evidence for activation of microglia in patients with psychiatric illnesses,” Neuroscience Letters, vol. 271, no. 2, pp. 126–128, 1999. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Radewicz, L. J. Garey, S. M. Gentleman, and R. Reynolds, “Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics,” Journal of Neuropathology and Experimental Neurology, vol. 59, no. 2, pp. 137–150, 2000. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Steiner, C. Mawrin, A. Ziegeler et al., “Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization,” Acta Neuropathologica, vol. 112, no. 3, pp. 305–316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Erhardt, K. Blennow, C. Nordin, E. Skogh, L. H. Lindström, and G. Engberg, “Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia,” Neuroscience Letters, vol. 313, no. 1-2, pp. 96–98, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. K. R. Linderholm, E. Skogh, S. K. Olsson et al., “Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia,” Schizophrenia Bulletin, vol. 38, no. 3, pp. 426–432, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Schwarcz, A. Rassoulpour, H.-Q. Wu, D. Medoff, C. A. Tamminga, and R. C. Roberts, “Increased cortical kynurenate content in schizophrenia,” Biological Psychiatry, vol. 50, no. 7, pp. 521–530, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Ceresoli-Borroni, A. Rassoulpour, H.-Q. Wu, P. Guidetti, and R. Schwarcz, “Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain,” Journal of Neural Transmission, vol. 113, no. 10, pp. 1355–1365, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. G. P. Amminger, M. R. Schäfer, K. Papageorgiou et al., “Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial,” Archives of General Psychiatry, vol. 67, no. 2, pp. 146–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. B. M. Ross, J. Seguin, and L. E. Sieswerda, “Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?” Lipids in Health and Disease, vol. 6, no. 1, article 21, pp. 1–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Peet, J. Brind, C. N. Ramchand, S. Shah, and G. K. Vankar, “Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia,” Schizophrenia Research, vol. 49, no. 3, pp. 243–251, 2001. View at Publisher · View at Google Scholar · View at Scopus
  80. J. K. Yao, S. Magan, A. F. Sonel, J. A. Gurklis, R. Sanders, and R. D. Reddy, “Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 71, no. 3, pp. 171–176, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. W. S. Fenton, F. Dickerson, J. Boronow, J. R. Hibbeln, and M. Knable, “A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia,” The American Journal of Psychiatry, vol. 158, no. 12, pp. 2071–2074, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Ehrenreich, D. Hinze-Selch, S. Stawicki et al., “Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin,” Molecular Psychiatry, vol. 12, no. 2, pp. 206–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Wüstenberg, M. Begemann, C. Bartels et al., “Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia,” Molecular Psychiatry, vol. 16, no. 1, pp. 26–36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Chaves, C. R. Marque, I. B. Chaudhry et al., “Short-term improvement by minocycline added to olanzapine antipsychotic treatment in paranoid schizophrenia,” Schizophrenia Bulletin, vol. 35, pp. 354–355, 2009. View at Google Scholar
  85. N. Ahuja and B. T. Carroll, “Possible anti-catatonic effects of minocycline in patients with schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 4, pp. 968–969, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Miyaoka, “Clinical potential of minocycline for schizophrenia,” CNS and Neurological Disorders—Drug Targets, vol. 7, no. 4, pp. 376–381, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. Levkovitz, S. Mendlovich, S. Riwkes et al., “A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia,” Journal of Clinical Psychiatry, vol. 71, no. 2, pp. 138–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. I. B. Chaudhry, J. Hallak, N. Husain et al., “Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment,” Journal of Psychopharmacology, vol. 26, no. 9, pp. 1185–1193, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. D. L. Kelly, G. Vyas, C. M. Richardson et al., “Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms,” Schizophrenia Research, vol. 133, no. 1–3, pp. 257–258, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. F. B. Dickerson, C. R. Stallings, J. J. Boronow, A. E. Origoni, and R. H. Yolken, “A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii,” Schizophrenia Research, vol. 112, no. 1–3, pp. 198–199, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. F. B. Dickerson, C. R. Stallings, J. J. Boronow, A. E. Origoni, A. Sullens, and R. H. Yolken, “Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus,” Schizophrenia Research, vol. 107, no. 2-3, pp. 147–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. W. Laan, D. E. Grobbee, J.-P. Selten, C. J. Heijnen, R. S. Kahn, and H. Burger, “Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 71, no. 5, pp. 520–527, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Weiser, S. Burshtein, L. Fodoreanu et al., “A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder,” Neuropsychopharmacology, vol. 28, pp. 314–446, 2012. View at Google Scholar
  94. C. E. Marx, R. S. E. Keefe, R. W. Buchanan et al., “Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia,” Neuropsychopharmacology, vol. 34, no. 8, pp. 1885–1903, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. C. E. Marx, D. W. Bradford, R. M. Hamer et al., “Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence,” Neuroscience, vol. 191, pp. 78–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. M. S. Ritsner, A. Gibel, T. Shleifer et al., “Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial,” Journal of Clinical Psychiatry, vol. 71, no. 10, pp. 1351–1362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Lavoie, M. M. Murray, P. Deppen et al., “Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients,” Neuropsychopharmacology, vol. 33, no. 9, pp. 2187–2199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Bulut, H. A. Savas, A. Altindag, O. Virit, and A. Dalkilic, “Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia,” The World Journal of Biological Psychiatry, vol. 10, no. 4, pp. 626–628, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. E. Ghafari, M. Fararouie, H. G. Shirazi, A. Farhangfar, F. Ghaderi, and A. Mohammadi, “Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized, placebo-controlled clinical trial,” Clinical Schizophrenia and Related Psychoses, vol. 6, no. 4, pp. 172–176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Kulkarni, E. Gavrilidis, W. Wang et al., “Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age,” Molecular Psychiatry, vol. 20, no. 6, pp. 695–702, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. C. M. Gibson, D. L. Penn, K. L. Smedley, J. Leserman, T. Elliott, and C. A. Pedersen, “A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia,” Schizophrenia Research, vol. 156, no. 2-3, pp. 261–265, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. U. Heresco-Levy, D. C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein, “Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia,” Archives of General Psychiatry, vol. 56, no. 1, pp. 29–36, 1999. View at Publisher · View at Google Scholar · View at Scopus
  103. J. T. Kantrowitz, A. K. Malhotra, B. Cornblatt et al., “High dose D-serine in the treatment of schizophrenia,” Schizophrenia Research, vol. 121, no. 1–3, pp. 125–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. G. N. Pachas, C. Cather, S. I. Pratt et al., “Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week open-label trial,” Journal of Dual Diagnosis, vol. 8, no. 2, pp. 117–125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. M. H. Schubert, K. A. Young, and P. B. Hicks, “Galantamine improves cognition in schizophrenic patients stabilized on risperidone,” Biological Psychiatry, vol. 60, no. 6, pp. 530–533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. F. M. Leweke, T. M. Odorfer, and J. M. Bumb, “Medical needs in the treatment of psychotic disorders,” Handbook of Experimental Pharmacology, vol. 212, pp. 165–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. J. M. Bumb, F. Enning, and F. M. Leweke, “Drug repurposing and emerging adjunctive treatments for schizophrenia,” Expert Opinion on Pharmacotherapy, vol. 16, no. 7, pp. 1049–1067, 2015. View at Publisher · View at Google Scholar · View at Scopus
  108. N. Müller, M. Riedel, C. Scheppach et al., “Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia,” American Journal of Psychiatry, vol. 159, no. 6, pp. 1029–1034, 2002. View at Publisher · View at Google Scholar · View at Scopus
  109. F. Rappart and N. Müller, “Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia,” Neuropsychopharmacology, vol. 29, no. 1, p. 222, 2004. View at Google Scholar
  110. M. H. Rapaport, K. K. Delrahim, C. J. Bresee, R. E. Maddux, O. Ahmadpour, and D. Dolnak, “Celecoxib augmentation of continuously Ill patients with schizophrenia,” Biological Psychiatry, vol. 57, no. 12, pp. 1594–1596, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. Y. Zhang, D. Chun Chen, Y. Long Tan, and D. F. Zhou, “A double-blind, placebo-controlled trial of celecoxib added to risperidone in first-episode and drug-naive patients with schizophrenia,” European Archives of Psychiatry and Clinical Neuroscience, vol. 256, no. 2, p. 50, 2006. View at Google Scholar
  112. S. Akhondzadeh, M. Tabatabaee, H. Amini, S. A. Ahmadi Abhari, S. H. Abbasi, and B. Behnam, “Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial,” Schizophrenia Research, vol. 90, no. 1–3, pp. 179–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. N. Müller, D. Krause, S. Dehning et al., “Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment,” Schizophrenia Research, vol. 121, no. 1–3, pp. 118–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. N. Müller, A. M. Myint, D. Krause, E. Weidinger, and K. J. Schwarz, “Anti-inflammatory treatment in schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 42, pp. 146–153, 2013. View at Publisher · View at Google Scholar
  115. S. Aïd and F. Bosetti, “Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications,” Biochimie, vol. 93, no. 1, pp. 46–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. L. Schwieler, S. Erhardt, C. Erhardt, and G. Engberg, “Prostaglandin-mediated control of rat brain kynurenic acid synthesis—opposite actions by COX-1 and COX-2 isoforms,” Journal of Neural Transmission, vol. 112, no. 7, pp. 863–872, 2005. View at Publisher · View at Google Scholar · View at Scopus
  117. S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987. View at Publisher · View at Google Scholar · View at Scopus
  118. W. Guy, “Clinical global impressions,” in ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ No ADM 76-338), pp. 218–222, National Institute of Mental Health, Rockville, Md, USA, 1976. View at Google Scholar
  119. H.-J. Möller, “Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia,” European Archives of Psychiatry and Clinical Neuroscience, vol. 251, no. 5, pp. 217–224, 2001. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Casolini, A. Catalani, A. R. Zuena, and L. Angelucci, “Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat,” Journal of Neuroscience Research, vol. 68, no. 3, pp. 337–343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  121. J. A. Lieberman, J. M. Alvir, A. Koreen et al., “Psychobiologic correlates of treatment response in schizophrenia,” Neuropsychopharmacology, vol. 14, no. 3, pp. 13–21, 1996. View at Publisher · View at Google Scholar · View at Scopus
  122. I. E. Sommer, L. De Witte, M. Begemann, and R. S. Kahn, “Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis,” Journal of Clinical Psychiatry, vol. 73, no. 4, pp. 414–419, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. T. Baheti, A. Nischal, A. Nischal et al., “A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia,” Schizophrenia Research, vol. 147, no. 1, pp. 201–202, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. S. E. Shoelson, L. Herrero, and A. Naaz, “Obesity, inflammation, and insulin resistance,” Gastroenterology, vol. 132, no. 6, pp. 2169–2180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. J. S. Smolen, D. Aletaha, M. Koeller, M. H. Weisman, and P. Emery, “New therapies for treatment of rheumatoid arthritis,” The Lancet, vol. 370, no. 9602, pp. 1861–1874, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. E. H. S. Choy and G. S. Panayi, “Cytokine pathways and joint inflammation in rheumatoid arthritis,” The New England Journal of Medicine, vol. 344, no. 12, pp. 907–916, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. C. L. Raison, R. E. Rutherford, B. J. Woolwine et al., “A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers,” JAMA Psychiatry, vol. 70, no. 1, pp. 31–41, 2013. View at Publisher · View at Google Scholar · View at Scopus